As shown in Figure 6C and 6D, combined treatment of Axl inhibition and PD-1 blockade resulted in the cure of one third of treated mice, and a delay of tumor growth and prolongation of their survival in the remaining mice (median survival time for vehicle, SGI-7079, R428, anti-PD-1, SGI-7079/anti-PD-1 and R428/anti-PD-1: 27, 54.5, 56, 78.5 days and not reached) while single treatment with anti-PD1 mAb showed negligible antitumor efficacy. Here, AXL is linked to neoplasm.